On May 12, 2023, Dr. Atul Goel, who was serving as the Director General of Health Services (DGHS) at the time and held the post until April 2025, issued a contentious circular that sent ripples through India’s healthcare system. The directive, addressed to Central Government Hospitals, CGHS Wellness Centers, and Polyclinics, mandated strict adherence to prescribing only generic medicines. The move, aimed at reducing healthcare costs and curbing pharmaceutical influence, has ignited a fierce debate among doctors, patients, and policymakers. While the government touts affordability and equity, critics argue the policy is premature, citing quality concerns, supply chain issues, and loss of medical autonomy.
The Circular’s Core: A Mandate for Generics
The circular reiterated a standing instruction: all doctors, including residents, in Central Government healthcare facilities must prescribe generic medicines only. Despite repeated directives, the DGHS noted persistent non-compliance, with some doctors continuing to prescribe branded drugs. This practice, the circular stated, was viewed “strictly” by the competent authority.
To ensure adherence, the circular instructed heads of institutions to monitor doctors closely and enforce strict compliance. The directive emphasised that prescribing generics was non-negotiable and those who prescribe branded drugs will be liable for further action. Additionally, the directive took aim at pharmaceutical marketing, banning medical representatives from visiting hospitals.
